Peptide Products

I. Mechanism of action (triple target synergy)

GLP-1: Suppresses appetite, delays gastric emptying, stimulates insulin secretion, lowers blood sugar.

- GIP: Enhances GLP-1 weight loss and improves insulin sensitivity.

- Pancreatic Glycogen (GCGR): Promotes fat breakdown, increases metabolic rate, reduces liver fat accumulation.

- Molecular characteristics: 39 amino acid peptide chains, fatty acid modified binding albumin, half-life of about 6 days, administration once a week.

II. Clinical efficacy (Phase III TRIUMPH-1,80 weeks)

- Applicable population: obese / overweight with at least one metabolic comorbidity (no diabetes).

- Dosage and weight loss:

4mg: Average weight loss of 17%.

9mg: Average weight loss of 24% (about 27 kg).

- 12 mg: Average weight loss of 28.7% (about 32 kg), the strongest weight loss drug currently.

- Additional benefits: significant improvements in blood sugar, lipids, blood pressure, fatty liver, knee arthritis pain and sleep apnea.

III. Use and Amount

- Mode of administration: Subcutaneous injection in the abdomen / thigh / upper arm, once a week for a fixed period of time.

- Dose titration: starting at 4 mg, up to 9 mg, 12 mg (maintenance) every 4-8 weeks.

IV. Safety and Side Effects

- Common: nausea, vomiting, diarrhoea, constipation, bloating (mild to moderate, with reduced tolerability).

- Rarely: low blood sugar (low risk), pancreatitis, gallbladder problems, injection site reactions.

Special: Skin paresthesia (numbness / tingling) occurs in about 5% of the 12 mg group.

- Contraindications: personal / family history of thyroid myeloid cancer, multiple endocrine adenomas type 2, pregnancy / lactation.

V. Indications (in research)

- Obesity / overweight long-term weight management.

- Glucose control for type 2 diabetes.

- metabolic-related fatty liver, knee osteoarthritis, obstructive sleep apnea, reduced cardiovascular risk.

VI. Status and purchase

Status: May 2026 Phase III successful, not approved by FDA / EMA / NMPA, only bedside trial available.

- Warning: Black market / generic safety risks are extremely high, with unknown ingredients, insufficient purity, and uncontrollable side effects.

VII. Comparative advantages (vs semaglutide / Tirzepatide)

Target: Triple (GIP + GLP-1 + GCGR) vs single / double.

Weight loss: 28.7% (12 mg) vs 15% -22%.

- Improved metabolism: stronger fat breakdown and lower liver fat.